14.6.2006

The drug CF101 is not metabolized in the liver and can be used as potential therapy for liver related conditions

Can-Fite BioPharma has recently completed preclinical trials to determine the in-vivo metabolism and elimination of its lead drug CF101, as part of preliminary trials leading to an upcoming phase IIb trial.

The abovementioned trial demonstrated that the drug is minimally metabolized in the liver and excreted intact in the urine, thus preventing adverse events. The stability of the drug in the liver may support its development as treatment for liver-related conditions (e.g. cirrhosis, liver cancer and type B and C hepatitis), based on the vast knowledge and experience gained by the company through various implementations of its drug platform .

Can-Fite CEO Prof. Pnina Fishman said this finding supports the company's development plans to promote CF101 as treatment for rheumatoid arthritis through the phase IIb trial and to add further indications for CF101 and introduce additional drugs into clinical practice, should it elect to do so.

About Can-Fite

Can-Fite BioPharma Ltd. is a public company, traded on the Tel-Aviv Stock Exchange that is headquartered in Petach-Tikva, Israel. The company, which began its operations at the end of 2000 was founded based on the work by Professor Pnina Fishman, formerly a Tumor Immunologist in the Rabin Medical Center and currently the company's CEO, together with Dr Ilan Cohn, Patent Attorney and Senior Partner at Reinhold Cohn and Partners, a leading Israeli Patent Attorney firm. The Company has research laboratories and offices in Israel. The Company's lead drug, CF101, for the treatment of rheumatoid arthritis is currently in Phase II clinical trials. The company is planning another clinical study in which CF101 will be tested for its efficacy in treating dry eye symptoms in patients having this diseaee

About CF101

CF101 is a small molecule, which is administered to patients orally. This drug, which is developed for the treatment of rheumatoid arthritis, was tested to date in clinical trials in the USA, UK and Israel. The drug is active against a wide variety of autoimmune and cancer diseases and has a preferential safety profile. The drug's main advantage is in its ability to specifically attack pathological cells without affecting healthy ones. In addition, the fact that the drug is administered orally in the form of a capsule creates a huge advantage vs. current treatments which are administered by IV infusion or injection, at much higher costs. The drug is developed for the treatment of

rheumatoid arthritis. The company also plans to shortly initiate another clinical study to test the drug's efficacy in treating dry eye symptoms of patients with this disease. The market of disease modifying anti-rheumatic drugs is estimated to be about US$ 7 billion per year and is expected to rise by about 20% annually. The market potential of drugs for treating dry eyes is also several billion dollars per year.

More information can be found at www.canfite.com.